无蛋白燕麦幼苗提取物对特应性皮炎患者微炎症及皮肤屏障功能的影响
特应性皮炎(AD)存在表皮屏障功能障碍及非皮损区亚临床微炎症,即使看似愈合的皮肤也需纳入治疗考量。润肤剂可安全有效改善屏障功能,推荐用于所有AD患者;中重度AD患者应将润肤剂与局部钙调神经磷酸酶抑制剂或局部糖皮质激素的主动治疗方案联合使用。含Rhealba燕麦幼苗提取物的润肤剂已显示抗炎和屏障修复特性,该提取物不含燕麦蛋白,可降低过敏反应风险。
要点
- AD非皮损皮肤存在亚临床微炎症和促炎细胞因子环境,即使看似愈合也需关注。
- 润肤剂通过提供外源性脂质改善屏障功能,推荐用于所有AD患者。
- 中重度AD患者应将润肤剂与局部钙调神经磷酸酶抑制剂或局部糖皮质激素的主动治疗方案联合。
核心结论
- 含Rhealba燕麦幼苗提取物的润肤剂具有抗炎和屏障修复特性,并已在针对AD微炎症的研究中进行了临床测试。
- 该提取物来自燕麦幼苗地上部分,不含燕麦蛋白,可降低过敏反应风险。
研究设计与样本
- 原文为综述性文章,未报告系统检索范围及纳入研究的具体设计。
主要发现
- AD患者非皮损皮肤显示亚临床炎症的组织学征象和促炎细胞因子环境。
- 润肤剂通过提供外源性脂质改善皮肤屏障功能。
- Rhealba燕麦幼苗提取物经特定工艺生产,可提取高水平黄酮类和皂苷等活性成分,同时几乎不含燕麦蛋白。
- 含Rhealba燕麦幼苗提取物的润肤剂已显示抗炎和屏障修复特性,并已在针对AD微炎症的研究中进行了临床测试。
关键数值与推荐
- 润肤剂推荐用于所有AD患者,不论整体疾病严重程度。
- 中重度AD患者应将润肤剂与局部钙调神经磷酸酶抑制剂或局部糖皮质激素的主动治疗方案联合使用。
- 急性发作期活动性湿疹皮损应首先接受每日抗炎治疗,之后再引入润肤剂,以快速缓解皮损和瘙痒。
- 看似愈合的AD皮损中持续存在的微炎症应采用主动治疗方法,包括最低限度抗炎治疗和每日大量使用润肤剂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atopic dermatitis (AD) is a common, highly pruritic, chronic inflammatory skin disease. Dysfunction of the epidermal barrier is witnessed by an increased transepidermal water loss in lesional and non-lesional AD skin. The inflammation in lesional AD skin is well characterized. Non-lesional skin of AD patients shows histological signs of a subclinical inflammation and a pro-inflammatory cytokine milieu. This microinflammation is present even in seemingly healed skin and must be taken into account regarding treatment of AD. Emollients provide a safe and effective method of skin barrier improvement, because they provide the skin with a source of exogenous lipids, thus improving its barrier function. The use of emollients is recommended for all AD patients irrespective of overall disease severity. Patients with moderate to severe AD should combine the emollients with a proactive therapy regimen of topical calcineurin inhibitors or topical corticosteroids. Skin areas affected by active eczema in flare should receive daily anti-inflammatory therapy first before introducing emollients, to induce rapid relief of skin lesions and pruritus. The microinflammation persisting in seemingly healed AD lesions should be addressed by a proactive treatment approach, consisting of minimal anti-inflammatory therapy and liberal, daily use of emollients. An emollient containing an extract of Rhealba oat plantlet has shown anti-inflammatory and barrier repairing properties, and was clinically tested in studies targeting the microinflammation in AD. All emollients based on Rhealba oat plantlet extract are free of oat protein, as the Rhealba extract is derived from the aerial parts of the oat plantlet and is unrelated to oatmeal proteins. The Rhealba oat plantlet extract is produced in a specific process, allowing the extraction of high levels of active principles such as flavonoids and saponins, whilst being virtually free of oat proteins to minimize the risk for allergic reactions.
引用
- Wollenberg A, Fölster-Holst R, Saint Aroman M, et al. Effects of a protein-free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2018. PMID: 29533490. doi:10.1111/jdv.14846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。